Female Sexual Dysfunction in Renal Failure

Evaluations of Sexual Dysfunction of Female in Chronic Renal Failure Clinical Trial

Official title:

Female Sexual Dysfunctions in Patients With Chronic Renal Failure

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03172637
• Other study ID #: FSDRF
• Status: Not yet recruiting
• Phase: N/A
• First received: May 30, 2017
• Last updated: May 30, 2017
• Start date: July 1, 2017
• Est. completion date: December 31, 2018

Study information

• Verified date: May 2017
• Source: Assiut University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

A myriad of sexual problems affect men and women with chronic kidney disease (CKD), including decreased libido, erectile dysfunction, dysmenorrhea, and infertility. Menstrual abnormalities are common in CKD and many women are an-ovulatory .

Causes of sexual dysfunction in CKD include hormonal alterations along with vascular, neurologic, psychogenic, and other factors, such as medications, contribute to the development of sexual dysfunction . Sexual dysfunction in females is mainly due to hormonal factors and manifests mainly as menstrual irregularities, amenorrhea, lack of vaginal lubrication, and failure to conceive.

Description:

Hormonal changes in chronic kidney disease are seen in prolactine, gonadotropins, and gonadal hormones. In women with CKD, elevated levels of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) are common. These hormonal changes are detected in the early stages of kidney disease and progressively worsen as kidney disease progresse .

. Women with chronic renal failure commonly have elevated circulating prolactin levels. As in men with chronic renal failure, the hypersecretion of prolactin in this setting appears to be autonomous, as it is resistant to maneuvers designed to stimulate or inhibit its release.

It has been suggested that the elevated prolactin levels may impair hypothalamic-pituitary function and contribute to sexual dysfunction and galactorrhea in these patients. However, uremic women treated with bromocryptine rarely resume normal menses and continue to complain of galactorrhea (if present), despite normalization of the plasma prolactin concentration. Thus, factors other than hyperprolactinemia must be important in this setting .

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 100
• Est. completion date: December 31, 2018
• Est. primary completion date: July 31, 2018
• Gender: Female
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• -Female patients with chronic renal failure (eGFR <15 ml/min/1.7m2 ) on dialysis or not.

• Age from 18 to 45 years old.

• Married.

• Sexually active during the last 6 monthes.

Exclusion Criteria:

• Pregnant women.

• Other medical diseases ( diabetes mellitus ,cardiac disorders ,neurological disorders and other systematic diseases).

• Taking medications affect sexuality function e.g. antidepressant drugs.

Related Conditions & MeSH terms

• Evaluations of Sexual Dysfunction of Female in Chronic Renal Failure
• Kidney Failure, Chronic
• Renal Insufficiency
• Renal Insufficiency, Chronic

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Esraa Ahmed Mohamed

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	effect of chronic renal failure in females on their sexuality function	compare sexuality function between female with chronic renal failure and normal female and observe difference between two groups	two years